Gastl G, Marth C, Leiter E, Gattringer C, Mayer I, Daxenbichler G, Flener R, Huber C
Cancer Res. 1985 Jul;45(7):2957-61.
Human recombinant gamma-interferon (rhu-IFN-gamma) and human recombinant alpha-interferon (rhu-IFN-alpha 2 arg) with a chemical purity of over 95% were compared for their antiproliferative and HLA-DR-inducing activity in five human breast cancer cell lines (BT 20, ZR 75.1, MCF 7, 734B, Hs578T). Cytostatic effects on tumor cells were evaluated in monolayer cultures. HLA-DR antigen expression was examined by an indirect immunofluorescence technique using two different anti-HLA-DR monoclonal antibodies (anti-HLA-DR, VID-1) against framework determinants. rhu-IFN-gamma and rhu-IFN-alpha 2 arg differed in their antiproliferative efficiency in terms of both dose dependency and the spectrum of sensitive target cells. Combinations of rhu-IFN-gamma and rhu-IFN-alpha 2 always resulted in higher cytostatic effects. HLA-DR expression was exclusively inducible by rhu-IFN-gamma and did not correspond to its antiproliferative activity. Furthermore, HLA-DR expression did not depend on proliferation but did require intact RNA and protein syntheses as shown by inhibition with cycloheximide and actinomycin D. HLA-DR antigen expression in mammary cancer lines was dependent on time, dose, and the continued presence of rhu-IFN-gamma. Thus, our data suggest that in particular combinations type I and type II interferons might be useful in the treatment of breast cancer because they provide effective cytostatic and cell membrane-modulating properties.
将化学纯度超过95%的人重组γ干扰素(rhu-IFN-γ)和人重组α干扰素(rhu-IFN-α2arg)在五种人乳腺癌细胞系(BT 20、ZR 75.1、MCF 7、734B、Hs578T)中进行抗增殖和诱导HLA-DR活性的比较。在单层培养中评估对肿瘤细胞的细胞抑制作用。使用两种针对构架决定簇的不同抗HLA-DR单克隆抗体(抗HLA-DR、VID-1),通过间接免疫荧光技术检测HLA-DR抗原表达。rhu-IFN-γ和rhu-IFN-α2arg在抗增殖效率方面,在剂量依赖性和敏感靶细胞谱方面存在差异。rhu-IFN-γ和rhu-IFN-α2的组合总是产生更高的细胞抑制作用。HLA-DR表达仅由rhu-IFN-γ诱导,且与其抗增殖活性不对应。此外,HLA-DR表达不依赖于增殖,但确实需要完整的RNA和蛋白质合成,如用环己酰亚胺和放线菌素D抑制所示。乳腺癌细胞系中的HLA-DR抗原表达取决于时间、剂量和rhu-IFN-γ的持续存在。因此,我们的数据表明,I型和II型干扰素的特定组合可能对乳腺癌治疗有用,因为它们具有有效的细胞抑制和细胞膜调节特性。